Head to Head Survey: IN8bio (NASDAQ:INAB) & Quince Therapeutics (NASDAQ:QNCX)

Quince Therapeutics (NASDAQ:QNCX) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Quince Therapeutics and IN8bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	4	2	3.33
IN8bio	0	0	1	0	3.00

Quince Therapeutics presently has a consensus price target of $9.50, indicating a potential upside of 588.41%. IN8bio has a consensus price target of $6.00, indicating a potential upside of 2,552.52%. Given IN8bio’s higher possible upside, analysts plainly believe IN8bio is more favorable than Quince Therapeutics.

Insider and Institutional Ownership

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by company insiders. Comparatively, 15.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Quince Therapeutics and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-53.27%	-22.73%
IN8bio	N/A	-197.15%	-130.48%

Risk and Volatility

Quince Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.

Valuation and Earnings

This table compares Quince Therapeutics and IN8bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.11
IN8bio	N/A	N/A	-$30.01 million	($0.58)	-0.39

Quince Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Summary

Quince Therapeutics beats IN8bio on 7 of the 12 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.